A pathway to precision therapy even for mitochondrial myoclonic epilepsy
- PMID: 31740382
- DOI: 10.1016/j.seizure.2019.11.001
A pathway to precision therapy even for mitochondrial myoclonic epilepsy
Conflict of interest statement
Declaration of Competing Interest NC and AO has any conflict of interest to disclose. PS received speaker fees and participated at advisory boards for Biomarin, Zogenyx, GW Pharmaceuticals, Lusofarmaco, and has received research funding by ENECTA srl, GW Pharmaceuticals, Kolfarma srl., Eisai.
Comment on
-
Mitochondrial myoclonic epilepsy requires specific treatment.Seizure. 2020 May;78:168-169. doi: 10.1016/j.seizure.2019.09.008. Epub 2019 Nov 15. Seizure. 2020. PMID: 31740381 No abstract available.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources